Pages that link to "Q40663897"
Jump to navigation
Jump to search
The following pages link to A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma (Q40663897):
Displaying 15 items.
- Tumor Restrictive Suicide Gene Therapy for Glioma Controlled by the FOS Promoter (Q27342367) (← links)
- Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation (Q34734168) (← links)
- Use of suicide genes for cancer gene therapy: study of the different approaches. (Q35753524) (← links)
- Promoters with cancer cell-specific activity for melanoma gene therapy (Q35944371) (← links)
- Non-viral vectors for cancer therapy (Q36456017) (← links)
- Electroporation-mediated gene therapy (Q36945857) (← links)
- Epigenetics and dermatological disease (Q37346201) (← links)
- Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity. (Q37579567) (← links)
- Bicistronic vector for combined expression of the HSVtk killer gene and cytokine GM-CSF gene in cancer cells (Q39472035) (← links)
- Antiglioma effects of combined use of a baculovirual vector expressing wild-type p53 and sodium butyrate (Q39603933) (← links)
- Systemic co-administration of depsipeptide selectively targets transfection enhancement to specific tissues and cell types (Q40248360) (← links)
- Histone deacetylase inhibitors preferentially augment transient transgene expression in human dermal fibroblasts (Q45870370) (← links)
- Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts (Q46383982) (← links)
- A Universal Tumor-Specific Promoter for Cancer Gene Therapy (Q59356934) (← links)
- Phase II trial of vorinostat in advanced melanoma (Q87166074) (← links)